Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Outcomes of COVID-19 Infection in Patients with Hematologic Malignancies

Elizabeth Behrens, MD, Anne Timmermann, Alexander Yerkan, Deborah A. Katz, MD, Agne Paner, MD, Melissa C. Larson, MD, Seo-Hyun Kim, MD, Shivi Jain, MDMBBS, Sefer Gezer, MD, Parameswaran Venugopal, MD, Irene Dehghan-Paz, Yoona Rhee, Celalettin Ustun, MD, Ankur Varma, Jamile M. Shammo, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-141063

Published: 2020

Journal Articles

Creating a Variant Database for the American Society of Hematalogy By Consensus Variant Classification of Common Genes Associated with Hematologic Malignancies

Niroshan Nadarajah, Alex Wagner, PhD, Rafael Bejar, MD PhD, Mark Ewalt, MD, Annette S. Kim, MD, Michelle M. Le Beau, PhD, Xiaotu Ma, PhD, Manja Meggendorfer, PhD, Jamile M. Shammo, MD, Gabriella Ryan, Alexa J. Siddon, MD, David P. Steensma, MD, Matthew J. Walter, MD, Ahmet Zehir, PhD, Jinghui Zhang, PhD, Torsten Haferlach, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-141204

Published: 2020

Journal Articles

Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US

Jessica J Jalbert, PhD, Umesh Chaudhari, MD, Haixin Zhang, MSc, Jonathan Weyne, MD, Jamile M. Shammo, MD

Blood (2019) 134 (Supplement_1): 3407.

https://doi.org/10.1182/blood-2019-125867

Published: 2019

Journal Articles

Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database

Blood (2019) 134 (Supplement_1): 2949.

https://doi.org/10.1182/blood-2019-121533

Published: 2019

Journal Articles

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Afoluso Ronnee Adesanya, MD, Patrick S. Zbyszewski, MBA, Richard C. Woodman, MD, Pierre Fenaux, MD PhD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 566.

https://doi.org/10.1182/blood-2019-131676

Published: 2019

Journal Articles

A Novel Patient Reported Outcome Instrument Assessing the Symptoms of Paroxysmal Nocturnal Hemoglobinuria

R Paola Daly, Jessica J Jalbert, PhD, Shannon Keith, Tara Symonds, Jamile M. Shammo, MD

Blood (2019) 134 (Supplement_1): 385.

https://doi.org/10.1182/blood-2019-125844

Published: 2019

Journal Articles

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Naveen Pemmaraju, MD, Yesid Alvarado, MD, Maro N. Ohanian, DO, Rosmy B. John, MSN, Patrick S. Zbyszewski, MBA, Manoj Maniar, PhD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2018) 132 (Supplement 1): 230.

https://doi.org/10.1182/blood-2018-99-119259

Published: 2018

Journal Articles

Analysis of Baseline Clinical Characteristics and Disease Burden in Patients Enrolled in the International Paroxysmal Nocturnal Hemoglobinuria Registry

Hubert Schrezenmeier, MD, Jaroslaw P. Maciejewski, PhD MD FACP, Alexander Roeth, MD, David J. Araten, MD, Yuzuru Kanakura, MD PhD, Loree Larratt, MD FRCP(C), Jamile M. Shammo, MD FASCP, FACP, Amanda Wilson, MPH, PhD, Gilda Shayan, Peter Hillmen, MBChB, PhD

Blood (2017) 130 (Supplement 1): 3488.

https://doi.org/10.1182/blood.V130.Suppl_1.3488.3488

Published: 2017

Journal Articles

RNA:m 5 c/Methyltransferases Mediate Chromatin Organization and 5-Azacytidine Response/Resistance in Leukemia

Jason Cheng, MD PhD, Li Chen, PhD MD, Yuan Li, MD, Ming Yue, PhD, Adam Cloe, MD, PhD, Jamile M. Shammo, MD FASCP, FACP, Richard A. Larson, MD, Chuan He, PhD, Michelle M. Le Beau, PhD, James W. Vardiman, MD

Blood (2017) 130 (Supplement 1): 2471.

https://doi.org/10.1182/blood.V130.Suppl_1.2471.2471

Published: 2017

Journal Articles

First Report of Severe Folate Deficiency in Women Treated with Olaparib for Relapsed Ovarian Cancer

Jamile M. Shammo, MD, Lydia Usha, MD, Kristin Richardson, MD, Elizabeth Jane Elliott, BS, DO, Parameswaran Venugopal, MD, Timothy M. Kuzel, MD, Melody Cobleigh, MD, Summer Dewdney, MD

Blood (2017) 130 (Supplement 1): 4748.

https://doi.org/10.1182/blood.V130.Suppl_1.4748.4748

Published: 2017

Journal Articles

Extended Duration of Anti-Thymocyte Globulin (ATG) Administration May Reduce the Risk of Graft-Versus-Host Disease in Patients with Aplastic Anemia Undergoing Matched-Related Allogeneic Peripheral Blood Stem Cell Transplantation

Laura A. Zider, MSN, ACNP-BC, RN, Amanda N. Seddon, PharmD, Sunita Nathan, MD, John J. Maciejewski, MD PhD, Jamile M. Shammo, MD, Gorgun Akpek, MD MHS

Blood (2016) 128 (22): 5876.

https://doi.org/10.1182/blood.V128.22.5876.5876

Published: 2016

Journal Articles

The Diagnostic Utility of Mutational Analysis in Patients with Suspected Myeloid Neoplasms, a Single Institution Experience

Jason Macklis, MD, Jamile M. Shammo, MD, Lela Buckingham, PhD, Parameswaran Venugopal, MD

Blood (2016) 128 (22): 5545.

https://doi.org/10.1182/blood.V128.22.5545.5545

Published: 2016

Journal Articles

A Striking Reduction of Monoclonal Protein in a Patient with Concurrent Plasma Cell Dyscrasia and CMML-2, after Treatment with Rigosertib (01910.Na)

Jamile M. Shammo, MD, Agne Paner, MD, MV Ramana Reddy, PhD, Rachel L Mitchell, MD, Parameswaran Venugopal, MD

Blood (2015) 126 (23): 5362.

https://doi.org/10.1182/blood.V126.23.5362.5362

Published: 2015

Journal Articles

Path to Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: The Results of an Exploratory Study Conducted By the Aplastic Anemia and Myelodysplastic Syndrome International Foundation and the National Organization for Rare Disorders Utilizing an Internet-Based Survey

Jamile M. Shammo, MD, Rachel L Mitchell, MD, Kylene Ogborn, RN, Ellen Salkeld, Stephanie Chisolm, PhD

Blood (2015) 126 (23): 3264.

https://doi.org/10.1182/blood.V126.23.3264.3264

Published: 2015

Journal Articles

A Report On a Phase 2 Trial Of Combination Therapy With Lenalidomide and Azacitidine In Patients With Non-Del 5q, Low Risk MDS

Jamile M. Shammo, MD, Kent W. Christopherson, II, PhD, Reem Karmali, MD, Melissa L. Larson, MD, Michelle Balla, Parameswaran Venugopal, MD

Blood (2013) 122 (21): 5232.

https://doi.org/10.1182/blood.V122.21.5232.5232

Published: 2013

Journal Articles

Incidence and Characteristics of Therapy-Related Myeloid Neoplasms in Patients with Non-Hodgkins Lymphoma Treated with Radioimmunotherapy

Salman Waheed, MD, Iva Ferreira, MD, Deborah A. Katz, MD, Reem Karmali, MD, Stephanie A. Gregory, MD, Parameswaran Venugopal, MD, Jamile M. Shammo, MD

Blood (2012) 120 (21): 4924.

https://doi.org/10.1182/blood.V120.21.4924.4924

Published: 2012

Journal Articles

Outcomes for Patients (Pts) with Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) with del5q Aged < 65 Years Treated with Lenalidomide (LEN) in MDS-003 and MDS-004: A Retrospective Combined Analysis

Pierre Fenaux, MD, PhD, Aristoteles Giagounidis, MD, Alan F. List, MD, Stephen D. Nimer, MD, Eva Hellström-Lindberg, Bayard L. Powell, MD, Xujie Yu, PhD, Barry Skikne, MD, Jamile M. Shammo, MD, Consuelo del Cañizo, MD

Blood (2011) 118 (21): 1723.

https://doi.org/10.1182/blood.V118.21.1723.1723

Published: 2011

Journal Articles

Prospective Study to Evaluate the Efficacy and Safety of Gemcitabine Combined with GMCSF and Rituximab in Heavily Pre-Treated Relapsed / Refractory B-Lymphoproliferative Disorders

Shinoj Pattali, MD, Stephanie A. Gregory, Melissa Leigh Larson, MD, Jamile M. Shammo, MD, Elena Bogdanova, CCRP, Teresa Obrien, RN, BS, Parameswaran Venugopal, MD

Blood (2011) 118 (21): 1616.

https://doi.org/10.1182/blood.V118.21.1616.1616

Published: 2011

Journal Articles

Lenalidomide-Induced Cytopenias In Patients with MDS Are Negatively Impacted by Reduced Glomerular Filtration Rate

Arlene Dawravoo, MD, Reem Karmali, MD, Amy Rizman, Stephanie A. Gregory, MD, Melissa L Larson, MD, Parameswaran Venugopal, MD, Jamile M. Shammo, MD

Blood (2010) 116 (21): 4958.

https://doi.org/10.1182/blood.V116.21.4958.4958

Published: 2010

Journal Articles

Tolerability of 2-Weekly CHOP+Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan (Zevalin) In Patients with Previously Untreated Diffuse Large B Cell Lymphoma (DLBCL): Final Analysis

Andrew Manson, Reem Karmali, MD, Irene Dehghan-Paz, MD, Eduardo Braun, MD, Teresa O'Brien, Stephanie A. Gregory, MD, Jamile M. Shammo, MD, Melissa L Larson, MD, Parmeswaran Venugopal, MD

Blood (2010) 116 (21): 4918.

https://doi.org/10.1182/blood.V116.21.4918.4918

Published: 2010

NARROW

Outcomes of COVID-19 Infection in Patients with Hematologic Malignancies

Creating a Variant Database for the American Society of Hematalogy By Consensus Variant Classification of Common Genes Associated with Hematologic Malignancies

Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US

Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

A Novel Patient Reported Outcome Instrument Assessing the Symptoms of Paroxysmal Nocturnal Hemoglobinuria

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Analysis of Baseline Clinical Characteristics and Disease Burden in Patients Enrolled in the International Paroxysmal Nocturnal Hemoglobinuria Registry

RNA:m 5 c/Methyltransferases Mediate Chromatin Organization and 5-Azacytidine Response/Resistance in Leukemia

First Report of Severe Folate Deficiency in Women Treated with Olaparib for Relapsed Ovarian Cancer

Extended Duration of Anti-Thymocyte Globulin (ATG) Administration May Reduce the Risk of Graft-Versus-Host Disease in Patients with Aplastic Anemia Undergoing Matched-Related Allogeneic Peripheral Blood Stem Cell Transplantation

The Diagnostic Utility of Mutational Analysis in Patients with Suspected Myeloid Neoplasms, a Single Institution Experience

A Striking Reduction of Monoclonal Protein in a Patient with Concurrent Plasma Cell Dyscrasia and CMML-2, after Treatment with Rigosertib (01910.Na)

Path to Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: The Results of an Exploratory Study Conducted By the Aplastic Anemia and Myelodysplastic Syndrome International Foundation and the National Organization for Rare Disorders Utilizing an Internet-Based Survey

A Report On a Phase 2 Trial Of Combination Therapy With Lenalidomide and Azacitidine In Patients With Non-Del 5q, Low Risk MDS

Incidence and Characteristics of Therapy-Related Myeloid Neoplasms in Patients with Non-Hodgkins Lymphoma Treated with Radioimmunotherapy

Outcomes for Patients (Pts) with Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) with del5q Aged < 65 Years Treated with Lenalidomide (LEN) in MDS-003 and MDS-004: A Retrospective Combined Analysis

Prospective Study to Evaluate the Efficacy and Safety of Gemcitabine Combined with GMCSF and Rituximab in Heavily Pre-Treated Relapsed / Refractory B-Lymphoproliferative Disorders

Lenalidomide-Induced Cytopenias In Patients with MDS Are Negatively Impacted by Reduced Glomerular Filtration Rate

Tolerability of 2-Weekly CHOP+Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan (Zevalin) In Patients with Previously Untreated Diffuse Large B Cell Lymphoma (DLBCL): Final Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only